| Autor: |
Rinella, Mary E., Castro Narro, Graciela E., Krag, Aleksander, Terrault, Norah, Newsome, Philip N. |
| Předmět: |
|
| Zdroj: |
Annals of Hepatology: Official Journal of the Mexican Association of Hepatology; Jul/Aug2024, Vol. 29 Issue 4, p2-3, 2p |
| Abstrakt: |
This document is a reply to a letter discussing the new definition of metabolic-associated fatty liver disease (MASLD). The authors of the reply defend the requirement of a cardiometabolic risk factor (CMRF) for the diagnosis of MASLD, stating that it is important for understanding the comorbidities associated with hepatic steatosis and for predicting outcomes. They argue that insulin resistance, while significant, may not be evident in routine testing and that other cardiometabolic risk factors should be considered. The authors also emphasize that MASLD overlaps almost entirely with non-alcoholic fatty liver disease (NAFLD) and that the new definition was designed to accommodate prior literature on NAFLD. The article discusses the proposed new nomenclature for steatotic liver disease (SLD) and its implications for clinical care and research. The authors argue that the new term, "metabolic dysfunction-associated steatotic liver disease" (MASLD), is clinically irrelevant and overlooks other potential causes of steatosis. They support maintaining the current alcohol thresholds for defining MASLD and emphasize the importance of cardiometabolic risk factors in disease incidence and progression. The authors also highlight the need for further research and validation in different contexts. They suggest that biomarkers and scores can be valuable tools for identifying hepatic steatosis, particularly in low- and middle-income countries where imaging may be less accessible. They emphasize the importance of multi-disciplinary collaboration and public health efforts in managing SLD and raising awareness among [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
